Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 64, Issue 9, 2005, Pages 1387-

  Gore, J ^a   Silver, R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; NITRATE; PENTOXIFYLLINE; SILDENAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HAND DISEASE; HUMAN; MALE; MORBIDITY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; THORAX PAIN; TREATMENT FAILURE; ULCER; WOUND HEALING;

ADULT; FEMALE; FINGERS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; RAYNAUD DISEASE; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SKIN ULCER; VASODILATOR AGENTS;

EID: 23944461780     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.034488     Document Type: Article

References (2)

1. Lichtenstein JR. Use of sildenafil citrate in Raynaud's phenomenon: Arthritis Rheum 2003;48:282-3.
2. Rybalkin S, Yan C, Bornfeldt K, Beavo J. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 2003;93:280-91.